M&A / Deals Ambrosia adds a megaround for obesity drugs BioPharma DiveThe $100 million Series B round will be used to bring the biotech s oral GLP-1 into early human testing.M&A / DealsMetabolic & GLP-1Read full story pharminent April 1, 2026 (Last updated: April 1, 2026) BioPharma Dive The $100 million Series B round will be used to bring the biotech s oral GLP-1 into early human testing. M&A / DealsMetabolic & GLP-1Read full story Post navigation Previous: FDA approves new high dose Spinraza regimen for SMANext: FDA Approves First New Molecular Entity Under National Priority Voucher Program Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026